“This patent further strengthens our intellectual property, which will be important as others and are drawn into space,” said Minimus Spine’s President and CEO David Hooper. “The subject matter included in this patent issued in Europe and Australia last year and we are pleased to be granted similar protection in the United States.”
Here are five quick facts on the patent:
1. The syringe cartilage maintains sterility of the syringe while the devices is processed within the Triojection console.
2. Triojection produces and measures ozone in a sterile syringe — the only system doing so.
3. The system has a CE mark and was used in the first cases last year.
4. Triojection is an alternative to surgery for patients with leg pain associated with disc herniation.
5. The initial feedback on procedures preformed last year were positive and the company is progressing on the European post-market study that will randomize patients to compare outcomes and costs associated with Triojection and surgical discectomy.
More articles on orthopedic devices:
Lumin Health names two new executives
Medtronic, LDR, Smith & Nephew & more—25 key notes
5 key trends in the global bio-implants market
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
